|
Mr. Holler was formerly the Chief Executive Officer and a founder of ID Biomedical Corporation and joined the Corriente Board of Directors in 2003. Dr. Holler held a number of executive positions with IDB, an integrated biotechnology company dedicated to the development of innovative vaccine products which operates in research, development, manufacturing, sales and marketing from its facilities in Canada and in the United States. After becoming CEO of ID Biomedical, the company grew from a market capitalization of approximately $50 Million to $1.7 billion, which was equal to the company’s takeover value paid by Glaxo Smith Klein.
Prior to founding IDB, Dr. Holler served as an emergency room physician at University Hospital at the University of British Columbia. He is a member of the British Columbia College of Physicians and Surgeons. | 